Intercell vaccine gets U.S. pediatric approval
VIENNA (Reuters) - Austria's Intercell said on Tuesday it has won U.S. regulatory approval for pediatric use of its Ixiaro vaccine to protect against Japanese Encephalitis (JE), a step it had achieved in Europe in February.
"For the first time in nearly two years, a licensed vaccine will now be available to vaccinate traveling children and children of forward-deployed military personal in Asia as well against JE," Chief Executive Thomas Lingelbach said in a statement, calling the step a key growth element for the product.
(Reporting by Michael Shields; Editing by David Cowell)
- Separatists take armored vehicles, humiliating Ukraine forces |
- Hundreds still missing in deadly Korea ferry sinking |
- Ocean floor search for missing Malaysia plane cut short again
- BofA reports first quarterly loss since 2011 on lofty legal bill
- Wall Street gains on Yellen comments and Yahoo; BofA falls